Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Popat

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Gut|January 14, 2005
Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndromeV Johnson, E Volikos, S E Halford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancerC Twelves, E Chmielowska, L Havel, et al.
Journal of Dental Research|February 2, 2023
High-Resolution Transcriptomic Landscape of the Human Submandibular GlandE Horeth, J Bard, M Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.
ESMO Open|June 7, 2023
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trialN Girard, S Ponce Aix, S Cedres, et al.
Leukemia|October 12, 1999
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemiaS Bevan, D Catovsky, A Marossy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient ProgrammeF Khan, C Ottensmeier, S Popat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743S Peters, A Scherpereel, R Cornelissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Gut|January 14, 2005
Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndromeV Johnson, E Volikos, S E Halford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancerC Twelves, E Chmielowska, L Havel, et al.
Journal of Dental Research|February 2, 2023
High-Resolution Transcriptomic Landscape of the Human Submandibular GlandE Horeth, J Bard, M Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.
ESMO Open|June 7, 2023
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trialN Girard, S Ponce Aix, S Cedres, et al.
Leukemia|October 12, 1999
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemiaS Bevan, D Catovsky, A Marossy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient ProgrammeF Khan, C Ottensmeier, S Popat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743S Peters, A Scherpereel, R Cornelissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Pageof 9